From: Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease
n = 29 | |
---|---|
Male sex (%) | 14 (48.3) |
Age at disease onset (mean ± SD, years old) | 36 ± 14 |
Body weight (kg) | |
Mean ± SD | 51.7 ± 11.1 |
Range | 32.0–78.0 |
Tobacco, nonsmoker (%) | 22 (75.9) |
Alcohol, nondrinker (%) | 17 (58.7) |
Age at initiation of anti-TNFα agent (mean ± SD, years old) | 42 ± 14 |
Disease duration before anti-TNFα agent (mean ± SD, years) | 6 ± 9 |
Type of anti-TNFα agent (IFX/ADA) administered | 16/13 |
Major symptoms | |
Ocular lesions (%) | 9 (31.0) |
Skin lesions (%) | 12 (41.4) |
Oral ulcers (%) | 28 (96.6) |
Genital ulcers (%) | 10 (34.5) |
Minor symptoms | |
Arthritis (%) | 8 (27.6) |
Vascular involvement (%) | 1 (3.4) |
HLA-B51 positivity (n = 21, %) | 5/21 (23.8) |
HLA-A26 positivity (n = 21, %) | 3/21 (14.3) |
Concomitant medication administered with the anti-TNFα agent | – |
Systemic corticosteroids (%) | 20 (69.0) |
≧ 20 mg corticosteroids (%) | 9 (31.0) |
5-Aminosalicylic acid (%) | 11 (37.9) |
CyA (%) | 2 (6.9) |
MTX (%) | 3 (10.3) |
Azathioprine/6-mercaptopurine (%) | 18 (62.1) |
Colchicine (%) | 16 (55.2) |
Previous major abdominal surgery (%) | 4 (13.8) |
baseline Global GI symptoms score (mean ± SD); score 0–4 | 1.69 ± 1.4 |
Baseline CRP level (mean ± SD, mg/dL) | 1.81 ± 3.8 |